PROCEPT BioRobotics is a growth-stage medical robotics company posting 20% revenue growth but in a confirmed falling-knife technical setup with a death cross, momentum score of only 3.0, volume surges on selloffs, and below-floor quality at 3.2 out of 10, making it a high-risk situation despite 30% analyst upside to target.
Thesis pillars
- Falling Knife Technical Setup→Stable
- Revenue Growth Moat Foundation→Stable
- Cash Burn Below Quality Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
PROCEPT BioRobotics Corporation (PRCT) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $16.80: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum.
PROCEPT BioRobotics develops and sells the AquaBeam and HYDROS Robotic Systems, which use Aquablation therapy — an image-guided, heat-free waterjet robotic procedure — to treat benign prostatic hyperplasia, with an installed base of 912 systems globally including 718 in the... Read more
Sell if holding. Engine safety override at $16.80: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Score 5.8/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About PROCEPT BioRobotics Corporation
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics' AquaBeam and HYDROS Robotic Systems, which deliver Aquablation therapy for benign prostatic hyperplasia, generated $308.1 million in revenue in 2025, up from $224.5 million in 2024. The company's installed base reached 912 robotic systems globally by December 31, 2025, with 718 units in the United States. Substantially all of that revenue comes from the robotic systems and their single-use disposable handpieces.
PROCEPT sells its robotic systems directly to hospitals in the United States, supplemented by ambulatory surgical centers, leasing companies, and, outside the U.S., a network of distribution partners; the company also offers sales-type leasing as an alternative to a direct capital purchase. Reimbursement flows through third-party payors — commercial insurers and government programs including Medicare, where all local Medicare Administrative Contractors issued positive local coverage determinations in 2021, extending coverage to eligible beneficiaries in all 50 states. The company estimates commercial payor coverage now reaches approximately 95% of men in the United States. Growth depends on converting the roughly 2,700 U.S. hospitals performing resective BPH procedures into system placements and then driving utilization of the single-use handpieces within each account, financed to date primarily through equity issuance and a term loan with Canadian Imperial Bank of Commerce.
Show full overview
PROCEPT's single largest exposure is not a therapeutic-area mix but a payer-coverage cliff: the 10-K states that if Medicare no longer covered its products, the impact on the business would be material, and it further warns that Medicare Administrative Contractors could revise the local coverage determinations issued in 2021 without notice. Because commercial payors typically follow Medicare's lead on emerging procedures, a reversal at the MAC level would not just shrink the roughly 95%-of-U.S.-men coverage footprint the company cites — it could stall hospital capital-equipment purchases altogether, given that reimbursement adequacy, not clinical efficacy, is what the filing identifies as the swing factor in hospital adoption.
See also: Healthcare · Medical Devices
From PROCEPT BioRobotics Corporation's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — PROCEPT BioRobotics Corporation
Latest news
- NEWS Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25 — benzinga Jul 6, 2026 negative
- NEWS This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday — benzinga Jun 24, 2026 positive
- NEWS This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday — benzinga Jun 24, 2026 positive
- NEWS Evercore ISI Group Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $30 — benzinga Jun 24, 2026 positive
- NEWS Top 3 Health Care Stocks You'll Regret Missing In Q2 — benzinga Jun 18, 2026 neutral
Generated 2026-07-26T05:12:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductrobotic systems and single-use disposable handpieces10-K Item 1A: 'substantially all of our revenue has been derived...from sales of our robotic systems and our accompanying single-use disposable handpieces'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -31.8%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.80: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Prior stop was $16.16. Score 5.8/10, moderate confidence.
Take-profit target: $25.49 (+52.7% upside). Prior stop was $16.16. Stop-loss: $16.16.
Concentration risk — Product: robotic systems and single-use disposable handpieces; Quality below floor (3.2 < 4.0).
PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -18.7). TrendMatrix value score: 8.7/10. Verdict: Sell.
22 analysts cover PRCT with a consensus score of 3.8/5. Average price target: $29.
What does PROCEPT BioRobotics Corporation do?PROCEPT BioRobotics develops and sells the AquaBeam and HYDROS Robotic Systems, which use Aquablation therapy — an...
PROCEPT BioRobotics develops and sells the AquaBeam and HYDROS Robotic Systems, which use Aquablation therapy — an image-guided, heat-free waterjet robotic procedure — to treat benign prostatic hyperplasia, with an installed base of 912 systems globally including 718 in the United States. The company sells primarily to hospitals through a direct sales force, supplemented by distribution partners and sales-type leasing arrangements, generating $308.1 million in revenue in 2025 versus $224.5 million in 2024.